Journal Title：Expert Review Of Gastroenterology & Hepatology

The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.

全世界胃腸道疾病給健康和經(jīng)濟帶來了巨大的負擔(dān)，因此需要高度關(guān)注病因、流行病學(xué)、預(yù)防、診斷、治療和新療法的開發(fā)。到上個世紀(jì)末，我們已經(jīng)看到了巨大的進步，無論是在疾病可視化技術(shù)方面，還是在胃潰瘍等領(lǐng)域的治愈療法方面，首先是 H2 拮抗劑的出現(xiàn)，然后是質(zhì)子泵抑制劑的出現(xiàn) - 這些都是醫(yī)學(xué)進步如何極大地造福患者的明顯例子。然而，專家們?nèi)悦媾R著來自各種病因的多種疾病的持續(xù)挑戰(zhàn)。

Expert Review Of Gastroenterology & Hepatology創(chuàng)刊于2007年，由Taylor and Francis Ltd.出版商出版，收稿方向涵蓋GASTROENTEROLOGY & HEPATOLOGY全領(lǐng)域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業(yè)認可度不錯，仍然是一本值得選擇的SCI期刊 。平均審稿速度 較慢,6-12周 ，影響因子指數(shù)3.8，該期刊近期沒有被列入國際期刊預(yù)警名單，廣大學(xué)者值得一試。